TerminatedPhase 2/3

Lamictal in the Treatment of Post-Herpetic Neuralgia

Stopped: enrollment difficult due to inclusion/exclusion criteria/protocol requirements

United StatesStarted 2005-02

Plain-language summary

To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in patients with post herpetic neuralgia.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients will be over the age of 18, * Need to have a diagnosis of Post-Herpetic Neuralgia, * Minimum of 4 on the Likert Pain Scale, * If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks Exclusion Criteria: * Currently on any antiepileptic drugs (AED), except for Gabapentin. * Currently taking opioid or unwilling to washout prior to the study, * Pregnant and lactating, * Have active severe systemic disease, * History of Stevens-Johnson syndrome or TEN, * Clinically significant abnormal lab values, * Known drug allergy to Lamictal, * Patients on Fibrates (Tricor and Lopid), * History of major psychiatric disturbance and substance abuse. * Valproate due to increase chances of severe rash, * Lidocaine Patch, * Use of hormonal contraceptives (birth control pills, patch, ring, injection)

Trial details

NCT IDNCT00295776

SponsorGeorge Washington University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-12

View on ClinicalTrials.gov More Neuralgia, Postherpetic trials